Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients

References

• Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853–60.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43: 27–34.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000;30(Suppl 1):S77–84.
   Google Scholar
• Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res 2010; 85:303–15.
   PubMed Web of Science ®Google Scholar
• Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis 2012;55:S33–42.
   PubMed Web of Science ®Google Scholar
• Weber R, Sabin CA, Friis-Moeller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632–41.
   PubMed Web of Science ®Google Scholar
• de Ledinghen V, Barreiro P, Foucher J, Labarga P, Castera L, Vispo ME, et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat 2008;15:427–33.
   PubMedGoogle Scholar
• Holmberg SD, Kathleen L, Xing J, Klevens M, Jiles R, Ward JW. The growing burden of mortality associated with viral hepatitis in the United States, 1999-2007. Presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 2011.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services (DHHS). February 2013. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• European AIDS Clinical Society (EACS) Guidelines, version 7.0. October 2013. Available at: http://www.eacsociety.org/Guidelines.aspx
   Google Scholar
• Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol 2010; 6:95–103.
   PubMed Web of Science ®Google Scholar
• Harijvan SG, Wanke R, Ferreira da Silva JL, Marques MM, Antunes AM. The phenolic metabolites of the anti-HIV drug efavirenz: evidence for distinct reactivities upon oxidation with Frémy's salt. Eur J Med Chem 2014;74:7–11.
   PubMedGoogle Scholar
• Rittweger M, Arastéh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007;46:739–56.
   PubMed Web of Science ®Google Scholar
• Ruela Corrêa JC, D’Arcy DM, dos Reis Serra CH, Nunes Salgado HR. Darunavir: a critical review of its properties, use and drug interactions. Pharmacology 2012;90: 102–9.
   PubMed Web of Science ®Google Scholar
• Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS 2012;7: 390–400.
   PubMed Web of Science ®Google Scholar
• Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, et al. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 2006;80:235–45.
   PubMed Web of Science ®Google Scholar
• Barreiro P, Rodriguez-Novoa S, Labarga P, Ruiz A, Jimenez-Nacher I, Martin-Carbonero L, et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis 2007:195:973–9.
   PubMed Web of Science ®Google Scholar
• Dominguez S, Ghosn J, Peytavin G, Guiguet M, Tubiana R, Valantin MA, et al. Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV-coinfected patients: the HEPADOSE study. J Antimicrob Chemother 2010;65:2445–9.
   PubMed Web of Science ®Google Scholar
• Pereira S, Caixas U, Branco T, Germano I, Lampreia F, Papoila AL, et al. Efavirenz concentrations in HIV-infected patients with and without viral hepatitis. Br J Clin Pharmacol 2008;66:551–5.
   PubMedGoogle Scholar
• Meynard JL, Lacombe K, Poirier JM, Legrand J, Morand-Joubert L, Girard PM. Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C. J Antimicrob Chemother 2009;63:579–84.
   PubMedGoogle Scholar
• Calza L, Mosca L, Pocaterra D, Piergentili B, Colangeli V, Manfredi R, et al. Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients. Eur J Clin Pharmacol 2011:67: 143–9.
   PubMedGoogle Scholar
• Casado JL, Del Palacio M, Moya J, Rodriguez JM, Moreno A, Perez-Elias MJ, et al. Safety and pharmacokinetics of lopinavir in HIV/HCV coinfected patients with advanced liver disease. HIV Clin Trials 2011;12:235–43.
   PubMed Web of Science ®Google Scholar
• Regazzi M, Villani P, Gulminetti R, Cusato M, Brandolini M, Tinelli C, et al. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens. Ther Drug Monit 2011;33:303–8.
   PubMedGoogle Scholar
• Di Biagio A, Rosso R, Loregian A, Pagni S, Sormani MP, Cenderello G, et al. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients. J Infect Chemother 2012;18: 587–90.
   PubMedGoogle Scholar
• Tommasi C, Nicastri E, Gallo AL. Raltegravir and darunavir plasma pharmacokinetic in HIV-1-infected patients with advanced liver disease. 11th International Workshop on Clinical Pharmacology and HIV Therapy, Sorrento, Italy, 2010.
   Google Scholar
• Hernandez-Novoa B, Moreno A, Perez-Elias MJ, Quereda C, Dronda F, Casado JL, et al. Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C). J Antimicrob Chemother 2014;69: 471–5.
   PubMed Web of Science ®Google Scholar
• Dickinson L, Robinson L, Tjia J, Khoo S, Back D. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;829:82–90.
   PubMed Web of Science ®Google Scholar
• Srivastava P, Moorthy GS, Gross R, Barrett JS. A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma. PLoS One 2013;8:e63305.
   Google Scholar
• Else L, Watson V, Tjia J, Hughes A, Siccardi M, Khoo S, et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:1455–65.
   PubMed Web of Science ®Google Scholar
• Ter Heine R, Hillebrand MJ, Rosing H, van Gorp EC, Mulder JW, Beijnen JH, et al. J Pharm Biomed Anal 2009;49:451–8.
   PubMedGoogle Scholar
• Borand L, Madec Y, Laureillard D, Chou M, Marcy O, Pheng P, et al. Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-Cipra KH001 Camelia Trial). PLoS One 2014;9:e90350.
   Google Scholar
• Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Decosterd LA. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71–5.
   PubMed Web of Science ®Google Scholar
• Ghosn J, Slama L, Chermak A, Houssaini A, Lambert-Niclot S, Schneider L, et al. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. J Med Virol 2013;85:8–15.
   PubMedGoogle Scholar
• Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and experienced patients. HIV Clin Trials 2008;9:418–27.
   PubMed Web of Science ®Google Scholar
• Croteau D, Letendre S, Best BM, Ellis RJ, Breidinger S, Clifford D, et al. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother 2010; 54:5156–60.
   PubMed Web of Science ®Google Scholar
• Crommentuyn KM, Kappelhoff BS, Mulder JW, Mairuhu AT, van Gorp EC, Meenhorst PL, et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2005;60: 378–89.
   PubMed Web of Science ®Google Scholar
• Wolfe R, Carlin JB. Sample-size calculation for a log- transformed outcome measure. Control Clin Trials 1999; 20:547–54.
   PubMedGoogle Scholar
• Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343–50.
   PubMed Web of Science ®Google Scholar
• Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc 2014;89:95–106.
   PubMed Web of Science ®Google Scholar
• van Luin M, Bannister WP, Mocroft A, Reiss P, Di Perri G, Peytavin G, et al. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. Antivir Ther 2009;14: 75–83.
   PubMedGoogle Scholar
• Habtewold A, Amogne W, Makonnen E, Yimer G, Nylén H, Riedel KD, et al. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. Pharmacogenomics J 2013;13:484–9.
   PubMed Web of Science ®Google Scholar
• Martín AS, Gómez AI, García-Berrocal B, Figueroa SC, Sánchez MC, Calvo Hernández MV, et al. Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics. Pharmacogenomics 2014;15:997–1006.
   PubMed Web of Science ®Google Scholar
• Donnerer J, Haas BJ, Kessler HH. Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir. Pharmacology 2008;82:287–92.
   PubMed Web of Science ®Google Scholar